Unterschiede

Hier werden die Unterschiede zwischen zwei Versionen gezeigt.

@@ Zeile 1: / Zeile 1: @@
+====== Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities ======
+===== ABSTRACT =====
+The ubiquitin proteasome system (UPS) plays a role in the regulation of most cellular pathways, and its deregulation has been implicated in a wide range of human
+pathologies that include cancer, neurodegenerative and immunological disorders and viral infections. Targeting the UPS by small molecular regulators thus provides an
+opportunity for the development of therapeutics for the treatment of several diseases. The proteasome inhibitor Bortezomib was approved for treatment of hematologic
+malignancies by the FDA in 2003, becoming the first drug targeting the ubiquitin proteasome system in the clinic. Development of drugs targeting specific components
+of the ubiquitin proteasome system, however, has lagged behind, mainly due to the complexity of the ubiquitination reaction and its outcomes. However, significant
+advances have been made in recent years in understanding the molecular nature of the ubiquitination system and the vast variety of cellular signals that it produces.
+Additionally, improvement of screening methods, both in vitro and in silico, have led to the disABSTRACT The ubiquitin proteasome system (UPS) plays a role in the regulation of most cellular pathways, and its deregulation has been implicated in a wide range of human
+pathologies that include cancer, neurodegenerative and immunological disorders and viral infections. Targeting the UPS by small molecular regulators thus provides an
+opportunity for the development of therapeutics for the treatment of several diseases. The proteasome inhibitor Bortezomib was approved for treatment of hematologic
+malignancies by the FDA in 2003, becoming the first drug targeting the ubiquitin proteasome system in the clinic. Development of drugs targeting specific components
+of the ubiquitin proteasome system, however, has lagged behind, mainly due to the complexity of the ubiquitination reaction and its outcomes. However, significant
+advances have been made in recent years in understanding the molecular nature of the ubiquitination system and the vast variety of cellular signals that it produces.
+Additionally, improvement of screening methods, both in vitro and in silico, have led to the discovery of a number of compounds targeting components of the ubiquitin
+proteasome system, and some of these have now entered clinical trials. Here, we discuss the current state of drug discovery targeting E3 ligases and the opportunities
+and challenges that it provides.covery of a number of compounds targeting components of the ubiquitin
+proteasome system, and some of these have now entered clinical trials. Here, we discuss the current state of drug discovery targeting E3 ligases and the opportunities
+and challenges that it provides.

Benutzer-Werkzeuge

Webseiten-Werkzeuge

Seitenleiste

Unterschiede

Seiten-Werkzeuge